Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 811 participants.
Also called NCT01499095
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 811 participants
- Sponsor
- Registry
-
NCT01499095 -
2010-023770-39
-
- Main results
- New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
- Other papers using this trial's data
- Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Chile, Finland, France, Germany, Hungary, Mexico, Portugal, Romania, Russia, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01499095. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2015-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
- Acronym
- EDITION II
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Lantus (Insulin glargine)
- Intervention (Drug)
- HOE901-U300 (new formulation of insulin glargine)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01499095- Content hash
14fbfcdd7b9003aa2c36f41791e913e1140546e48c3dc6fb12d257b5c30cd244